|Awarded On||February 21, 2019|
|Title||Improving Safety and Efficacy of Amino Acid Depletion Therapy for Acute Lymphoblastic Leukemia Using Translatable Nanotechnology|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Jacques Lux|
Acute lymphoblastic leukemia (ALL) accounts for more than 25% of all pediatric cancers. ALL cancer cells grow and multiply in the bone marrow crowding out normal blood cell production. To multiply, ALL cancer cells rely upon a constant supply of nutrients and amino acids – the building blocks of proteins. Specifically, asparagine that can be manufactured by normal cells to meet their normal growth and function, cannot be made by ALL cancer cells. The current therapeutic strategy is to eliminate access of ALL cancer cells to asparagine, is accomplished by injecting asparaginase, an enzyme that degrades asparagine, causing ALL cancer cells to die without harming normal cells. This therapy is u...